Drugs / Chlorzoxazone
Chlorzoxazone
also known as
Clorzoxazona · NSC-26189 · Paraflex · Parafon · Parafon forte dsc · Parafon-forte · Relaxon · Strifon · +1 more
Small molecule targets KCNN4 via activation
Regulatory milestones approvals, filings & regulatory actions · 1 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Approved | US (FDA) | PARAFON FORTE DSC | — | 1958-08-15 | fda.gov ↗ |
Trials 4
195719581959196019611962196319641965196619671968196919701971197219731974197519761977197819791980198119821983198419851986198719881989199019911992199319941995199619971998199920002001200220032004200520062007200820092010201120122013201420152016201720182019202020212022202320242025202620272028
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT03103568 | Mar → Jun 2017 | — | Swedish Orphan Biovitrum | Completed | No outcome recorded |
| Phase 42 trials | ||||||
| Phase 4 | NCT02291666 | Apr 2015 → Jul 2019 | type 2 diabetes mellitus | University of Montreal Hospital Centre (CHUM) | Completed | No outcome recorded |
| Phase 4 | NCT01342341 | Apr 2011 → Apr 2013 | alcohol abuse | University of California, San Francisco | Completed | No outcome recorded |
| Phase not applicable1 trial | ||||||
| — | NCT03563287 | Jan 2012 → Dec 2014 | morbid obesity | University of Eastern Finland | Completed | No outcome recorded |
| Comparator or background therapy4 trials | ||||||
| Phase 1 | NCT01187862 Background | Jul 2010 → Feb 2011 | — | University Hospital, Basel, Switzerland | Completed | No outcome recorded |
| Phase 4 | NCT07109882 Comparator | Jul → Aug 2025 overdue | bruxism | University of Baghdad | Recruiting | No outcome recorded |
| Phase 4 | NCT02405104 Comparator | Sep 2015 → Dec 2017 | osteoarthritis, hip, osteoarthritis, knee | Northern Orthopaedic Division, Denmark | Completed | No outcome recorded |
| Phase 4 | NCT01933542 Comparator | Aug 2013 → Aug 2015 | — | Rigshospitalet, Denmark | Completed | No outcome recorded |
Evidence & citations 14 cited values
Every value below carries the sentence it was read from. 9 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | chlorzoxazone | “Two equally loaded capsules containing: Melatonin (2.0 mg) Nicotine (1.0 mg) Bupropion (37.5 mg) Repaglinide (0.25 mg) Losartan (12.5 mg) Omeprazole (10 mg) Chlorzoxazone...” NCT03563287 ↗ |
| Known as | Clorzoxazona | ChEMBL registry synonym — accepted as the source's own label CHEMBL1371 ↗ |
| Known as | NSC-26189 | ChEMBL registry synonym — accepted as the source's own label CHEMBL1371 ↗ |
| Known as | Paraflex | ChEMBL registry synonym — accepted as the source's own label CHEMBL1371 ↗ |
| Known as | Parafon | ChEMBL registry synonym — accepted as the source's own label CHEMBL1371 ↗ |
| Known as | Parafon forte dsc | ChEMBL registry synonym — accepted as the source's own label CHEMBL1371 ↗ |
| Known as | Parafon-forte | ChEMBL registry synonym — accepted as the source's own label CHEMBL1371 ↗ |
| Known as | Relaxon | “the first group will receive Relaxon (chlorzoxazone) twice daily for two weeks” NCT07109882 ↗ |
| Known as | Strifon | ChEMBL registry synonym — accepted as the source's own label CHEMBL1371 ↗ |
| Known as | Strifon forte dsc | ChEMBL registry synonym — accepted as the source's own label CHEMBL1371 ↗ |
| Action | Activate | “Intermediate conductance calcium-activated potassium channel protein 4 opener” CHEMBL1371 ↗ |
| Modality | Small molecule | — CHEMBL1371 ↗ |
| Route | Oral | “Oral administration of chlorzoxazone 500 mg” NCT01933542 ↗ |
| Target | KCNN4 | “Intermediate conductance calcium-activated potassium channel protein 4 opener” CHEMBL1371 ↗ |